These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39373088)

  • 1. Indirect costs assessment and intangible costs description of rheumatoid arthritis patients with biological therapy in Morocco: ECORAM Study.
    Zarrik H; Hassani AC; Rkain H; Allali F; Bahiri R; Ahid S
    Int J Rheum Dis; 2024 Oct; 27(10):e15367. PubMed ID: 39373088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
    Hu H; Luan L; Yang K; Li SC
    Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.
    Fellous S; Rkain H; Ahid S; Abouqal R; Tahiri L; Hmamouchi I; Achemlal L; El Bouchti I; El Maghraoui A; Ghozlani I; Hassikou H; Harzy T; Ichchou L; Mkinsi O; Niamane R; Bahiri R; Allali F
    Rheumatol Int; 2021 Apr; 41(4):787-793. PubMed ID: 33386900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
    Hallert E; Husberg M; Kalkan A; Skogh T; Bernfort L
    Scand J Rheumatol; 2014; 43(3):177-83. PubMed ID: 24354438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Socioeconomic impact of rheumatoid arthritis in Morocco.
    Rkain H; Allali F; Jroundi I; Hajjaj-Hassouni N
    Joint Bone Spine; 2006 May; 73(3):278-83. PubMed ID: 16376598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of cost structures in rheumatoid arthritis over the past decade.
    Huscher D; Mittendorf T; von Hinüber U; Kötter I; Hoese G; Pfäfflin A; Bischoff S; Zink A;
    Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
    Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
    Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
    Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.
    Mattila K; Buttgereit F; Tuominen R
    Rheumatol Int; 2015 Nov; 35(11):1791-7. PubMed ID: 26007151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
    Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
    Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
    Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
    Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
    Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
    Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.